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For more than a decade, it has been apparent that
apoptosis and other forms of cell death are often con-
trolled at one or more crucial steps involving the
mitochondria. Recent findings, including an elegant
investigation in a recent issue of Cell (Hao et al.,
2005), have helped to elucidate fundamental aspects
of this involvement while raising puzzling new ques-
tions about mitochondrial routes to cellular demise.
The emerging, if preliminary, perspective these new
studies provide may represent either a refinement of
our views of how cells die or, perhaps, the beginnings
of what amounts to a reformulation of our ideas.
The basic mitochondrial pathway of apoptosis in verte-
brates (Danial and Korsmeyer, 2004) begins with the per-
meabilization of the mitochondrial outer membrane by
proapoptotic members of the Bcl-2 family, resulting in
a release of proteins from the intermembrane space
into the cytosol. Among these released proteins is cyto-
chrome c, which interacts with monomeric APAF-1 to
facilitate a conformational change in the latter, leading
to its oligomerization and recruitment of caspase-9 to
form the apoptosome (Figure 1). The associated cas-
pase-9 is thereby activated, and this in turn cleaves and
activates the executioner caspases-3 and -7. These
then cleave key substrates in the cell to produce the
cellular and biochemical events we see as apoptosis.
Other released proteins facilitate caspase activation
through inactivation of endogenous inhibitors of cas-
pases, the inhibitor of apoptosis proteins (IAPs). While
activated executioner caspases clearly kill cells via
apoptosis, inhibition of these proteinases only tran-
siently protects cells; once the mitochondria permeabil-
ize, death will proceed regardless of caspase activa-
tion, either due to other toxic mediators released from
the mitochondria or eventual loss of essential mito-
chondrial functions (Chipuk and Green, 2005).
The entire process, from the initial trigger to the de-
struction of the cell, can take hours or even days. But
the events that concern us here, beginning with the first
mitochondrial changes and culminating in the activa-
tion of caspases, often take about ten minutes, and it
is strongly suspected that once these events proceed
to the point of executioner caspase activation without
constraint, the death of the cell may be inevitable. Here,
I discuss recent findings regarding these ten minutes,
including caspase activation and the signals that cause
mitochondrial outer membrane permeabilization (MOMP).
Along the way we explore what may be simple detours
from the road to ruin, or might represent important al-
ternate routes to cellular destruction.*Correspondence: doug@liai.orgShadow of a Doubt: Cytochrome c and APAF-1
At the core of the mitochondrial pathway of apoptosis
is the cytosolic function of cytochrome c to activate
caspases via APAF-1, a function that is distinct from
that of mitochondrial cytochrome c in electron trans-
port. This distinction allowed Hao et al. (2005) to gener-
ate a mouse expressing a mutant cytochrome c (K72A)
capable of sustaining mitochondrial respiration but
lacking APAF-1-activating potential. Developmental ab-
normalities in these mice generally resemble those of
APAF-1 and caspase-9-deficient animals, providing
support for the core mitochondrial pathway in an espe-
cially elegant manner.
Presently, we know of only one way in which cas-
pase-9 can be activated, leading to apoptosis: cyto-
chrome c induces the oligomerization of APAF-1, which
recruits and dimerizes caspase-9, and this association
activates the caspases. It is important to note that un-
like the executioner caspases, initiator caspases such
as caspase-9 cannot be activated by being cleaved—
activation requires active dimerization by an adaptor
molecule (Fuentes-Prior and Salvesen, 2004). There-
fore, while cleavage of caspase-9 can be observed in a
variety of settings, the only known adaptor/activator for
caspase-9 is APAF-1 that has been triggered by cyto-
chrome c.
By careful examination of the phenotypes and prop-
erties of mouse mutants of the three key players (cy-
tochrome c, APAF-1, caspase-9), however, we may get
glimpses of alternative routes to APAF-1 and/or cas-
pase-9 activation. Depending on the strain background,
these animals can often survive to birth and mature,
albeit with growth and behavioral abnormalities that are
due to developmental defects in the hypothalamus
(Hao et al., 2005)). An analysis of the response to dif-
ferent apoptosis inducers in cytochrome c mutant and
APAF-1 null thymocytes showed intriguing differences
that may suggest alternatives to the canonical pathway.
While cell death in APAF-1 null thymocytes was de-
layed in response to multiple proapoptotic agents, the
cytochrome c mutant cells died under some of these
conditions (Hao et al., 2005). Can APAF-1 be activated
independently of cytochrome c?
If so (and I consider the alternative below), it may be
that such a mechanism constitutively activates APAF-1
at low levels. A recent structural and biochemical study
of truncated APAF-1, lacking its WD domain, shows the
role of dATP (and ATP) in APAF-1 activation and how
this may relate to cytochrome c binding (Riedl et al.,
2005). The nucleotide binding site in APAF-1 is essen-
tial for its function, and hydrolysis of dATP (and ATP)
by the molecule results in its unfolding. The APAF-1 WD
presumably masks the nucleotide binding site, and cy-
tochrome c remains the only molecule known to react
and unmask it. However, if the nucleotide can somehow
gain access to the site independently of cytochrome c,
APAF-1 activation should be possible. One way might
be the expression of an isoform of APAF-1 lacking this
inhibitory function of the WD region; however, none of
the several isoforms of APAF-1 that have been de-
scribed have such constitutive activity.
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672Figure 1. Mitochondrial Roads to Ruin
Two related ways in which mitochondria contribute to cell death
are pictured. In the first, mitochondrial outer membrane permeabili-
zation (MOMP) occurs when the proapoptotic Bcl-2 family proteins
Bax and/or Bak are activated by BH3-only proteins in response to
apoptosis-inducing signals. This results in the release of proteins
of the mitochodrial intermembrane space, including cytochrome c,
Smac/DIABLO, andOmi/HtrA2. Cytochrome cactivatesAPAF-1,which
oligomerizes to form an apoptosome, that in turn recruits and acti-
vates caspase-9. The activated caspase-9 cleaves and activates
executioner caspases. Inhibitor of apoptosis proteins (IAPs) block
caspase-9 function, and this is disinhibited by Smac and Omi. A
second pathway to cell death is triggered by conditions that en-
gage the mitochondrial permeability transition in the mitochondrial
inner membrane, leading to matrix swelling and rupture of the outer
membrane. This death pathway appears to engage a necrotic form
of death. While evidence suggests that these two mitochondrial
pathways are distinct, it is suspected that there is significant over-
lap between them.
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BNevertheless, if such low level activation of APAF-1
does indeed occur, the cytochrome c-independent acti-
vation of caspase-9 in this setting might be expected
to be regulated by the IAPs, such as X-linked IAP
(XIAP), that bind and block caspase function. The situa-
tion may be analogous to what is thought to occur in
Drosophila apoptosis; a constitutively active APAF-1
homolog, ARK, triggers the caspase-9 homolog, DRONC,
whose activity is held in check by an IAP (DIAP-1) (Danial
and Korsmeyer, 2004). Apoptosis proceeds only when
the caspase-IAP interaction is blocked. In the case of
vertebrate cells, several proteins are known that can
compete for IAPs and thereby derepress caspase acti-
vation. These proteins, such as Smac/DIABLO and
Omi/HtrA2, are all found sequestered in the mitochon-
drial intermembrane space, and they are released upon
MOMP. Therefore, in our speculative scenario, apopto-
sis might proceed via engagement of the mitochondrial
pathway, independently of cytochrome c.
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tThis scenario is testable. Several synthetic, cell-per-eable IAP antagonists have been developed, and they
re described to trigger caspase activation and apo-
tosis in transformed lines. If these similarly trigger
poptosis in cytochrome c mutant cells (but not, say, in
PAF-1 null cells), this would provide support for the
bove model. However, in such a setting, inhibition of
aspases by pharmacologic inhibitors should preserve
lonogenic survival of the cells since the ensuing death
f the cells is predicted to be completely dependent
n caspase activation. This prediction of the effects of
aspase inhibitors on cellular survival in the presence
f IAP antagonists (even in wild-type cells) remains to
e evaluated.
However, before we delve too far into these specu-
ations it might be useful to sound a note of caution.
he idea that APAF-1 is activated in cytochrome c mu-
ant mice does not necessarily prove that APAF-1 is
riggered independently of cytochrome c. As noted above,
t is likely that cytochrome c binds to the APAF-1 WD to
nmask the nucleotide binding site. It remains possible
hat the K72A mutant of cytochrome c, while having
reatly reduced binding to the APAF-1 WD, neverthe-
ess displaces it to some extent, allowing nucleotide
ccess in some situations. Indeed, this mutant cyto-
hrome c has been shown to trigger caspase activation
n cell extracts, albeit at higher concentrations than are
ormally required for wild-type cytochrome c (Abdul-
aev et al., 2002). Therefore, cells with mutant cyto-
hrome c may activate APAF-1 and caspases in some
ut not all cases. For example, K72A mutant cells that
ontain (and release) higher levels of cytochrome c
ight activate caspases, or if elevated amounts of dATP
r ATP (or perhaps other more arcane nucleotides) are
resent this may compensate for the reduced activity
f the mutant cytochrome c. Thus, it may not be neces-
ary to speculate that APAF-1 is activated indepen-
ently of cytochrome c, but only that the K72A mutant
f cytochrome c is able to activate APAF-1 in only
ome circumstances.
Another fundamentally interesting observation is also
eported by Hao et al. (2005). Bone marrow from the
ytochrome c mutant animals, transplanted into wild-
ype recipients, gave rise after a year to a pronounced
and T cell hyperplasia, splenomegaly, and lymphad-
opathy. While we do not know if the same phenotype
ould be seen with long-term transplantation of APAF-1-
r caspase-9-defective bone marrow (published ac-
ounts, which did not report such effects, examined
uch shorter time periods [Scott et al., 2004]), the ob-
ervations lead to an idea of a “trickle” of apoptosis in
ild-type lymphocytes that is missing in the mutant an-
mals.
There are only two broad explanations for this phe-
omenon, both extremely interesting: (1) lymphoid cells
hat are destined to die via the mitochondrial pathway
ay undergo MOMP but may sometimes survive and
ecover proliferative potential, provided that caspases
re not induced, or (2) the mutant cytochrome c has a
urvival activity in the mitochondria that is not shared
y wild-type cytochrome c, resulting in enhanced sur-
ival upstream of MOMP. The first possibility would be
upported by a similar effect in APAF-1- or caspase-9-
eficient cells, which have not been fully examined in
his way. Alternatively, if this effect is specific to the
mutant cytochrome c (and not APAF-1- or caspase-9
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673null cells), then the second possibility should be con-
sidered. Although this mutant appears to have normal
electron transport activity (Hao et al., 2005), any “stall-
ing” might ultimately impact on the function of complex
II, which has recently been shown to have important
tumor suppressor activity by limiting the accumulation
of succinate in the cell (Selak et al., 2005). If, in the
mutant cells, succinate accumulates (say, in lympho-
cytes, which depend more on glycolysis than on oxida-
tive phosphorylation for their energy), this may lead to
HIF-1α stabilization by succinate-mediated inhibition of
the prolyl hydroxylase required for HIF-1α degradation
(Selak et al., 2005). HIF-1α, in turn, promotes cellular
survival and could promote the accumulation of acti-
vated lymphocytes in these mice. Indeed, HIF-1α stabi-
lization has been shown to block activation-induced apo-
ptosis in T cells, and therefore its stabilization would
be expected to result in an accumulation of memory T
cells as described (Hao et al., 2005). A careful examina-
tion of the respiratory activity of mitochondria from cy-
tochrome c mutant mice shows a slight depression in
succinate-driven complex II activity (Hao et al., 2005),
perhaps supporting this novel idea.
Cytochrome c Release: Double Indemnity
The results from Hao et al. (2005) help to keep cyto-
chrome c center stage in the mitochondrial pathway of
apoptosis. Early in the “ten minutes” that concern us
here, the proteins of the mitochondrial intermembrane
space, including cytochrome c, are released in a sud-
den, all-or-nothing manner. In general, two nonexclu-
sive models have been proposed for how the process
of MOMP proceeds. In one, proapoptotic members of
the Bcl-2 family act to create discontinuities (perhaps
pores) in the mitochondrial outer membrane, without
affecting the functions of the inner membrane or matrix.
In the second, a variety of signals (Ca2+, reactive oxy-
gen species, and many others) trigger the opening of
small channels in the mitochondrial inner membrane,
allowing water to enter and swell the matrix, effectively
bursting the outer membrane, an effect called the mito-
chondrial permeability transition (mPT). Both models
have been widely invoked to explain MOMP in different
settings, resulting in apoptosis via the mitochondrial
pathway.
Two recent papers have greatly refined this view. In
both, mice were generated with targeted disruption of
cyclophilin D, a mitochondrial matrix protein involved
in mPT (Baines et al., 2005; Nakagawa et al., 2005). As
expected the mitochondria from these mice were com-
pletely resistant to the induction of mPT by a range of
agents. Nevertheless, induction of MOMP by the pro-
apoptotic Bcl-2 family members Bax and Bid (dis-
cussed in more detail below) proceeded normally
(Baines et al., 2005; Nakagawa et al., 2005). Further,
and perhaps more impressively, all forms of apoptosis
in a range of cells types, as well as all developmentally
controlled apoptosis, occurred identically to that seen
in wild-type cells from various tissues (Nakagawa et al.,
2005). Thus, mPT appears to be irrelevant for the en-
gagement of the mitochondrial pathway of apoptosis.
This conclusion, while valid as a first approximation,
can only be formally drawn for those forms of mPT that
are depedent on cyclophilin D.
Notably, however, not all cell death in these mice pro-ceeds normally. Another significant form of cell death,characterized as necrosis (based on morphology and
lack of an effect of caspase inhibitors on the tempo and
mode of death), such as that induced by high doses
of hydrogen peroxide, did not proceed in these cells.
Strikingly, these mice were remarkably resistant to isch-
emia/reperfusion injury in the heart (Baines et al., 2005;
Nakagawa et al., 2005). The unavoidable conclusion is
that cyclophilin D-dependent mPT is fundamental to a
mitochondrial pathway of necrotic cell death.
The human intellect is drawn to dichotomies: the
mitochondrial pathway of apoptosis involves an mPT-
independent MOMP (see below), while the mitochon-
drial pathway of necrosis depends on and is caused by
an mPT. However, things may not be so simple. The
mitochondrial pathway of apoptosis is dependent on
the proapoptotic Bcl-2 family proteins Bax and Bak (so
called “multidomain” or BH123 proteins, see below),
and the antiapoptotic Bcl-2 family members (such as
Bcl-2 itself) block MOMP and this mitochondrial path-
way. But Bcl-2 has also been shown to suppress cell
death in the same heart ischemic/reperfusion model
used in the cyclophilin D-knockout studies. Therefore
modifiers of Bcl-2 function (such as the proapoptotic
Bcl-2 family members) might impact on this mode of
cell death. (However, ischemic injury elicits a surround-
ing apoptosis that might be the true target of Bcl-2 in
this setting, and therefore this is by no means proof of
an effect of Bcl-2 on a mitochondrial pathway of ne-
crotic death dependent on cyclophilin D). Further, mPT-
induced MOMP results in the release of cytochrome c
(and all other intermembrane space proteins) and can
therefore engage the mitochondrial pathway of cas-
pase activation. That this was not observed with high-
dose hydrogen peroxide may be a consequence of the
direct inhibitory effects of oxygen on the active site of
caspases. “Grey zones” may thus exist where an mPT
that is insufficient to engage necrotic death may never-
theless result in apoptosis. Future studies using these
cyclophilin D-defective animals may help to define
these “grey zone” deaths.
With respect to apoptosis, the process of MOMP
therefore apparently depends entirely on the function
of Bax and Bak to disrupt the barrier function of the
outer mitochondrial membrane. Early notions that this
was a function of the levels of Bax/Bak versus antiapo-
ptotic proteins (e.g., Bcl-2, Bcl-xL, Mcl-1) envisioned a
“rheostat” where death is controlled by changing the
levels (and or functions) of the antiapoptotic Bcl-2 fam-
ily members. Such inhibition of antiapoptotic activity is
mediated by the BH3-only subfamily of the Bcl-2 pro-
teins, which share only the third Bcl-2 homology do-
main with other family members. These bind to the anti-
apoptotic Bcl-2 proteins and neutralize their activity.
Recent studies by two groups add complexity to this
simple rheostat model (Chen et al., 2005; Kuwana et al.,
2005). In the first, a survey of the BH3-only proteins
and their interactions with several antiapoptotic Bcl-2
family proteins revealed a specificity of interactions
where some BH3-only proteins interact with only a sub-
set of antiapoptotic proteins (Chen et al., 2005). Inhibit-
ing multiple antiapoptotic Bcl-2 proteins appears to be
required for apoptosis, such that death is controlled by
the pattern of functions of these antagonistic players.
However, is the neutralization of antiapoptotic Bcl-2family proteins sufficient for apoptosis? Bax in its na-
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674tive, cytosolic, and monomeric form is not constitu-
tively active but must be activated if it is to permeabil-
ize the mitochondrial outer membrane and cause
apoptosis (Kuwana et al., 2005). (It is presumed, but not
proven, that Bak shares this requirement.) The activa-
tion of Bax can be triggered by BH3-only proteins, but
again, there appears to be specificity in this interaction.
Of those examined, only Bid and Bim were observed
to have this function, leading to their designation as
“activator” BH3-only proteins. Others (Bad, Puma,
Noxa, Bmf, Hrk) did not but instead appeared to per-
form their function as suggested above, through neu-
tralization of antiapoptotic Bcl-2 proteins. These “dere-
pressor” BH3-only proteins were seen to sensitize cells
for apoptosis while not being directly toxic on their
own. The emergent view is one of Bax/Bak activation
by activator BH3-only proteins that is antagonized by
antiapoptotic Bcl-2 proteins and in turn promoted by
derepression by other BH3-only proteins.
Cell Death and Society
There is a fundamental problem with multicellular life;
selection for cell survival in proliferating cells can be
antithetical to the survival of the individual. In the evolu-
tion of multicellular individuality, the selective pressures
on the cell lineages had to be subsumed in the interest
of organismal integrity (Buss, 1987). This problem is
solved by how our cells are “wired”; survival of a cell is
dependent on the availability of factors produced by
other cells, often belonging to distinct lineages. This
social interaction among cells ensures that each lin-
eage tends to be held in check, the default being death
(Raff, 1992).
This idea, that death is a default (which appears to
be at least superficially true at the cellular level), may
not be true at the molecular level. In the absence of
signals to trigger the activation of Bax and Bak, apo-
ptosis via the mitochondrial pathway will not occur. In-
deed, cells lacking Bax and Bak when deprived of
growth and survival factors, persist for long periods of
time, fueling their metabolic needs through autophagy
(Lum et al., 2005). In theory, the same would probably
be true of cells lacking signals to activate Bax and Bak.
These signals are probably not restricted to the activa-
tor BH3-only proteins, but at this point we do not know
how many different types of “activators” there are. The
alternative idea, that Bax and Bak are constitutively
active and are simply held in check by the antiapoptotic
Bcl-2 family proteins (the “rheostat” model in its sim-
plest form), is not supported by biochemistry—Bax and
Bak are not found in association with antiapoptotic
Bcl-2 family members in healthy cells. Apoptosis via
the mitochondrial pathway only happens when a posi-
tive signal to activate Bax and/or Bak occurs and pro-
ceeds without inhibition.
Therefore, in the absence of activation of Bax/Bak it
is life, not death, that is the cellular default, and cells
will catabolize themselves in order to survive. It follows,
then, that the cellular society that is multicellular life is
sustained to some extent by the activation of Bax and
Bak under conditions of limiting survival signals. Depri-
vation of survival factors actively generates a trigger for
Bax and Bak activation, rather than simply removing
the antiapoptotic functions of Bcl-2 and related mole-
cules.
These considerations do not appear to include the
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Smitochondrial pathway of necrotic death, which is notngaged by deprivation of survival factors and does not
ppear to play a role in normal development (Baines et
l., 2005; Nakagawa et al., 2005). Perhaps this is not
urprising since this form of cell death is potently in-
lammatory, as evidenced (for example) by the effects
f ischemic injury. In contrast, mPT-less MOMP that is
ediated through the actions of Bcl-2 family proteins
riggered in the course of cellular socialization (e.g.,
rowth factor deprivation) does not induce inflamma-
ion and therefore silently participates in normal devel-
pment and homeostasis.
These are emerging views of the “ten minutes” in
he death of a cell that include MOMP, cytochrome
-induced activation of APAF-1, and caspase activa-
ion—ten minutes that can occur at any time following
he induction of apoptosis by a stress or other death
ignal but that probably condemn the cell to its demise.
hat determines when and if a cell will face these cru-
ial ten minutes remains murky, and we simply do not
now in most cases why MOMP and its consequences
ccur at a particular time hours (or days) after a cell is
riggered to die. As we refine our understanding of this
ritical event, however, we reach new levels of appreci-
tion of the delicate balance that is cellular survival in
he complex multicellular individual.
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